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GIIfI ine to what extent intermittent administration of dDmipramine, during the luteal phase only, is also Iftdive against premenstrual complaints. Twenty-nine ..dtpressed women displaying severe premenstrual iriMbility and/or depressed mood and fulfilling the DSM·/ll ·R criteria of late luteal phase dysphoric disorder IrIr treated daily from the day of ovulation until the .n of the menstruation either with clomipramine (25 � 7S mg) (n = 15) or with placebo (n = 14) for three III/StCU tive menstrual cycles; another nine subjects (seven • cIomipramine, two on placebo) dropped out during lIJIment. In both treatment groups self-rated rmnmstrual irritability and depressed mood (as laived December 10, 1992; revised April 27, 1993; accepted May 5,1993 . 11993 American College of Neuropsychopharmacology Nished by Elsevier Science Publishing Co., Inc .
• Avenue of the Americas, New York, NY 10010 registered daily using a visual analogue scale) were significantly reduced during treatment; in the placebo group, this symptom reduction was about 45%, whereas in the clomipramine group it was greater than 70%. The mean premenstrual ratings of irritability and depressed mood during the three treatment cycles were significantly lower in the clomipramine group than in the placebo group. Also with respect to the rating of global improvement, the result obtained with clomipramine was significantly better than that obtained with placebo. The study confirms the previously reported effectiveness of low doses of clomipramine in the treatment of premenstrual syndrome and demonstrates that the time lag between onset of medication and clinical effect is shorter when clomipramine is used for premenstrual syndrome than when it is used for depression, panic disorder, or obsessive compulsive disorder . [Neuropsychopharmacology 9:133-145, 1993J The cardinal symptoms of the premenstrual syndrome (PMS), or late luteal phase dysphoric disorder (LLPDD), are irritability and depressed mood; in addition, ten sion, increased carbohydrate craving, sleep distur bance, and a sense of bloating are common complaints. For fulhllment of the diagnosis, the symptoms should start regularly around ovulation or during the two weeks preceding the menstrual bleeding and terminate within a few days after the onset of menstruation (Frank 1931; Halbreich et a1. 1982 ; American Psychiatric As sociation 1985).
Most women of fertile age experience mild premen-0893-133X/93/$6.00 strual complaints (Reid 1985; Andersch et al. 1986; Chi hal 1987) ; needless to say, a majority of these women are capable of mastering their symptoms without medi cation. However, several independent studies indicate that as much as 10% of all menstruating women have premenstrual complaints of such severity that they would like to medicate to reduce them (Reid 1985; An dersch et al. 1986; Chihal 1987) .
In a recent open study (Eriksson et al. 1990) , fol lowed by a confIrmative placebo-controlled trial (Sund blad et al. 1992) , we have shown that daily intake throughout the menstrual cycle of low doses of the an tidepressant clomipramine very effectively reduces premenstrual sadness and irritability in nondepressed women suffering from LLPDD. It was hypothesized that the impressive effect of clomipramine in reducing premenstrual complaints was mainly due to the sero tonin reuptake inhibiting effect of the drug.
In spite of the comparatively low doses used in these studies (25 to 75 mg per day), side effects of the treatment were not uncommon. For this reason, sev eral of the participating women expressed the opinion that intermittent administration of the drug during the premenstrual phase only would be more attractive than a medication given also during the symptom-free follic ular phase. As judged by the clinical profIle of clomi pramine when used for the treatment of depression, panic disorder , and obsessive compulsive disorder (OCD) (Katz et al. 1990 ), one would not expect such a noncontinuous medication to be effective; thus, in most trials, clomipramine, like other monoamine reuptake inhibitors, requires at least 2 to 3 weeks of treatment to exert marked clinical effects. Hence, we were surprised when a sma ll group of women with severe premenstrual complaints during an open pilot trial indeed reported a marked effect of clomipra mine also when the drug was taken in the luteal phase only (Sundblad and Eriksson, unpublished fInding) . To investigate whether this response is indeed related to the pharmacodynamics of clomipramine or is merely a placebo effect, the present controlled trial of intermit tent administration of clomipramine in severe LLPDD was undertaken.
SUBJECTS AND METHODS

Recruitment and Inclusion Criteria
Women with premenstrual irritability and/or depressed mood were recruited by means of a newspaper adver tisement followed by a brief telephone interview and a subsequent, extensive, structured interview. The pri mary inclusion criteria were severe irritability and/or depressed mood starting regularly around ovulation or during the 2 weeks preceding the menstrual bleeding and terminating within a few days after the onset of NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO.1 menstruation as reported by the patient during the inter, view. In addition, the criteria of LLPDD in DSM-III·R (American Psychiatric Association 1985) should be fulhlled. Exclusion criteria were: 1) previous or ongoing psychiatric illness (apart from major depressive disor· der or dysthymic disorder), 2) ongoing major depres· sive disorder or dysthymic disorder (as defIned using DSM-III-R and by means of the Montgomery-A sberg Depression Scale), 3) major depressive disorder or dys thymic disorder less than 2 years from the time of the interview, 4) ongoing medication for somatic or psy· chiatric illness, 5) ongoing medication with oral con· traceptives, 6) ongoing alcohol abuse, 7) ongoing so matic illness, 8) irregular menstruations, 9) ongoing or planned pregnancy, 10) less than 18 years of age, and 11) previous treatment with antidepressants for premen strual complaints. Informed consent was obtained from all participants.
Before starting medication, all participants per· formed daily rating with respect to the possible occur· rence of irritability, depressed mood, tension, increased appetite and/or carbohydrate craving, breast tender· ness, and bloating, respectively, for two subsequent menstrual cycles using a visual analogue scale (V AS) (0 to 100 mm; 0 mm = no complaints, 100 mm = maxi· mal complaints). Subjects not displaying the following evidence of menstrually related changes during both reference cycles were excluded from the study. 1) More than a 100% increase in either irritability or depressed mood (or both) during the premenstrual phase (calcu· lated as the mean rating of the 5 days before the 1st day of menstruation) as compared to the postmenstr u� phase (calculated as the mean rating of days 6 to 1001 the cycle; cycle day 1 = the 1st day of menstruation). 2) Mean premenstrual rating of irritability or depressed mood exceeding 20 mm. In addition, some participants were excluded during the course of the two reference cycles due to other reasons (such as pregnancy and on· set of depression).
Immediately after the second reference cycle, the participants fulfIlling the inclusion criteria were ran· domized either to the clomipramine or to the placelxJ group. For practical reasons a number of participants were included in the randomization before having com pleted the rating of the second reference cycle; some of these turned out to display an unsatisfactory symp tom rating during the reference cycles and were hence excluded in spite of the fact that they had been part 01 the randomization.
Medication
After the 2 months of symptom rating, medication started for patients not excluded due to unsatisfactoli rating (or other reasons) during the reference cycles. Tablets containing placebo and clomipramine, respec' li¥eIy, were identical in shape, size, and color, and both piie nts and investigators were unaware of whether the filient was given placebo or clomipramine until the lludy was completed. Treatment started at the esti lilted time of ovulation (14 days before expected men lInIation) and continued until the start of menstrua PI. On the frrst day of medication, the patients were ilslructed to take one tablet containing 5 mg of clomi pramine (or placebo). The following day, the patients 10k two tablets each containing 5 mg of clomipramine (arplacebo). The third day of medication, the patients 10k one tablet containing 25 mg clomipramine (or Jkebo). From the fourth day of treatment and onwards troughout the entire premenstrual period the patients were instructed to take two tablets each containing 25
IIIg of clomipramine (or placebo). However, patients eperiencing marked side effects of the treatment were ilstructed to decrease the dose to one tablet daily. On !he other hand, patients experiencing no or mild side 6cts and an unsatisfactory reduction of premenstrual amplaints during the course of the fIrst premenstrual phase were in structed to increase the dosage from two "three tablets daily. Thus, the dosage applied was flex tie; two tablets (50 mg of clomipramine) being the ICOmmended dose and one (25 mg) and three (75 mg) 1Iblets, res pectively, being the minimal and maximal _all owed. At the fIrst day of menstruation, the pa ... ts were to reduce the dose to one tablet containing !mg(or placebo), the second day of menstruation the Jlllien ts took one tablet containing 10 mg of clomipra line (or placebo), whereas the third day of menstrua Dt the dose was 5 mg of clomipramine (or one tablet afplacebo). From the fourth day of menstruation until !he estimated day of ovulation the patients were free lanmedication. The same tablet regimen was repeated _g the two following treatment cycles.
Sam Drug Concentrations fwdetermination of serum levels of clomipramine and ismetabolite desmethylclomipramine, blood samples me obtained in the morning 1 to 5 days before the ImStrual bleeding during treatment cycle 3; the pre Clding intake of medication had occurred 8 PM the mning before. Serum levels of clomipramine and des lelhyldomipramine were measured using gas chroma .phy as previously described (Nyberg and Mar Bsso n 1984). The lower detection limit was 10 nM for � cl omipramine and desmethylclomipramine.
ltd Assessment �g the three treatment cycles the participants per irmed daily symptom ratings using the same 1 to 100
• VAS (comprising the items irritability, depressed 1IIOd , tension, increased appetite/carbohydrate cravClomipramine in the Premenstrual Syndrome 135 ing, breast tenderness, and bloating) as during the two pretreatment reference cycles. In addition, symptoms were rated also during one additional drug-free refer ence cycle after the three cycles of medication were com pleted. To obtain a global assessment of possible drug effects, all patients were asked to estimate how they felt with respect to their premenstrual complaints dur ing treatment as compared to how they felt before (enor mously improved = 7, much improved = 6, somewhat improved = 5, no change = 4, somewhat deteriorated = 3, much deteriorated = 2, enormously deteriorated = 1) within 2 weeks after the last treatment cycle. The spouses of all cohabiting participants were asked to per form an independent rating of the premenstrual con dition of the patient with respect to irritability and depressed mood once every reference and treatment cycle using a 1 to 100 mm VAS. It was emphasized that this rating should be based on the spouse's own obser vations and that it should not be influenced by any preceding discussion between patient and cohabitor. Spouse's ratings were not mandatory.
Tolerability Assessment
Before the start of the trial, the participants were in formed of the various side effects that could be expected from treatment with clomipramine and instructed to report, by telephone Lall or by a note in the symptom assessment form, any symptom appearing during medication for which there were no other obvious ex planation. To what extent certain specmed side effects were present was never actively inquired by the inves tigators.
Statistics
For statistical comparisons within and between the two treatment groups, the mean rating during the 5 days preceding the menstrual bleeding in each treatment cy cle was used as a measure of premenstrual symptoma tology, whereas the mean rating of cycle day 6 to 10 was used as a measure of postmenstrual complaints.
Within both treatment groups, the premenstrual symptom rating scores during the two reference cycles (mean of both cycles) were compared with the symp tom rating during each of the three different treatment cycles as well as with the mean of all three treatment cycles using Wilcoxon signed rank test. In addition, the mean of the three treatment cycles was compared with the rating of the posttreatment reference cycle using the same statistical test.
With respect to the following items, the two treat ment groups were compared with each other using the Mann-Whitney U test. 1) pre-and postmenstrual rat ing of the six symptoms inquired (irritability, depressed mood, tension, increased appetite/carbohydrate crav-ing, breast tenderness, bloating) during each reference cycle, during each treatment cycle, and during the post treatment reference cycle, 2) the mean premenstrual symptom rating of the two pretreatment reference cy cles and of the three treatment cycles (all six symptoms), respectively, 3) global improvement or deterioration, as rated by the patient shortly after the last treatment cycle, 4) spouse's rating of irritability and depressed mood before (mean of both reference cycle ratings) and during (mean of all available treatment cycle ratings) medication,S) maximal dose of test drug or placebo.
In line with the protocol for the trial, only patients completing the study were included in the primary effect assessment. p values less than .05 were regarded as statistically signifIcant.
RESULTS
Number of Drop Outs and Fulftllers
Of 64 women recruited by means of a telephone in terview and a structured interview (see Methods), nine women for varying reasons chose not to participate in the study. Another 17 subjects were excluded from the study for one or several of the following reasons. 1)
They were found to fulfill one or more of the exclusion criteria during the two pretreatment reference cycles (see Methods). 2) They were found not to display a men- strually related cyclical pattern with respect to irri tabil ity and/or depressed mood (as defmed in Methods) duro ing the two initial reference cycles.
Thirty-eight subjects started medication with either clomipramine (n = 22) or placebo (n = 16). The uneven distribution of subjects between the two treatment groups was accidental and due to the fact that randomi zation for some subjects was undertaken before they were excluded due to unsatisfactory rating during the two reference cycles.
Two placebo treated patients dropped out during the study; one because of side effects and one because of pregnancy. In the clomipramine group, seven pa tients dropped out; six because of side effects and Oli because of pregnancy. Consequently, 29 patients (15 on clomipramine and 14 on placebo) fulftll ed the trial. secutive pretreatment reference cycles (RCI and RC2) and during the posttreatment reference cycle (RC3), no treatmed was given, whereas in the treatment cycles (TCI to TC3) the patients were medicated with clomipramine or placebo pre menstrually. Levels of signifIcance (clomipramine group versus placebo group) for the premenstrual phases of each cyti
were: RCI NS, RC2 NS, TCI P = .04, TC2 NS (p = .1), TC3 p = .03, RC3 NS. For levels of signifIcance when comparq the ratings of the reference cycles with the rating of the treatment cycles within each treatment group, see Resu l ts.
poup five subjects had chosen a plateau dose of three IIbIetsdaily, whereas the remaining nine subjects took .,tablets as maximal dose. In the clomipramine group, flrUpatients the plateau dose was 50 mg/day whereas 6ree patients did not take more than 25 mg/ day. The lference between the two groups in number of tablets den daily was statistically signifIcant (p = .0007).
W".runeach treatment group, a similar plateau dose was
INChed in each treatment cycle: clomipramine 45.7 ± 19m9 (cycle 1), 48. 3 ± 3.8 mg (cycle 2), and 50.0 ± 15 mg (cycl e 3); placebo 2.6 ± 0.1 table (cycle 1), 16 ± 0. 1 table (cycle 2), and 2.5 ± 0.1 tabl (cycle 3).
The number of days on medication did not differ G1nilicantly between groups: clomipramine 12.6 ± 0.9 kyde l), 12. 1 ± 0. 8 (cycle 2), and 13.1 ± 0.9 (cycle 3); �ebo 13. 0 ± 0. 6 (cycle 1), 14.0 ± 0.7 (cycle 2), and 121 ± 0. 8 (cycle 3). The pre-and postmenstrual symptom rating (mean of 5 days; see Methods) of premenstrual irritability, depressed mood, tension, and increased appetite and/or carbohydrate craving during the two pretreat ment reference cycles, the three treatment cycles, and the posttreatment reference cycle, are shown in Figures  1 to 4 . In addition, to illustrate the temporal relation between start of medication and onset of drug action, the daily irritability and depressed mood ratings throughout the study (group means) are shown in fig  ure 5 . In both treatment groups, the mean ratings of premenstrual irritability, depressed mood, tension and increased appetite/carbohydrate craving during the three treatment cycles were signifIcantly lower than the mean ratings of the two pretreatment reference cycles (see Figures 1 to 4) J9ae 2. Means of self-rated depressed mood (VAS 0 to 100 mm) of cycle day 6 to 10 (follicular phase) and of the 5 days fRCfding the day of the menstruation (luteal phase). The bars represent group means with standard errors. During the troronsecutive pretreatment reference cycles (RCI and RC2) and during the posttreatment reference cycle (RC3), no treat nntwasgiven, whereas in the treatment cycles (TCI to TC3) the patients were medicated with clomipramine or placebo pmenstrually. Levels of signifIcance (clomipramine group versus placebo group) for the premenstrual phases of each cycle biyp = .001, depressed mood p = .002, tension p = JI2. increased appetite/carbohydrate craving p = 01).
Neither in the clomipramine group nor in the placebo pp did the rating of the third treatment cycle differ �cantly from the rating of the fIrst treatment cycle Whrespect to any of these four symptoms. During the posttre atment reference cycle, a reappearance of symptoms was observed in both groups. Thus, in the clomi pramine group the mean rating of the posttreatment reference cycle was signifIcantly higher than that of the three treatment cycles with respect to irritability (p = .003), depressed mood (p = .008), tension (p = .009), and increased appetite/carbohydrate craving (p = .03).
In the placebo group the mean rating of the posttreat- sis, the mean premenstrual rating of these symptoms during the three treatment cycles, but not the mean rat· ing during the pretreatment reference cycles or during the posttreatment reference cycle, was signifIcantly lower in the clomipramine group than in the placebo group (p = .04).
Breast Tenderness and Bloating
The mean premenstrual ratings of the somatic symp toms breast tenderness and bloating during treatment cycles 3 to 5 were signifIcantly lower than the corre sponding rating during the pretreatment reference cycles in the clomipramine group (both symptoms: p = .003) but not in the placebo group (Figs. 6 and 7) . How ever, when interpreting this difference in symptom de crease between the two groups, it should be noted tha t both these symptoms accidentally were more common in the clomipramine group than in the placebo group during the pretreatment reference cycles (although this difference did not reach statistical signifIcance). When the clomipramine and placebo groups were compared with respect to mean premenstrual ratings of breast tenderness and bloating during the three treatmentcy· cles, no statistically signifIcant differences were ob "'" 7. Means of self-rated bloating (V AS 0 to 100 mm) of cycle day 6 to 10 (follicular phase) and of the 5 days preceding 6tday of the menstruation (luteal phase). The bars represent group means with standard errors. During the two consecu I!ft pretreatment reference cycles (RCl and RC2) and during the posttreatment reference cycle (RC3), no treatment was "". whereas in the treatment cycles (TCl to TC3) the patients were medicated with clomipramine or placebo premenstrually.
Il&rences be tween the two treatment groups never reached statistical signifIcance . For levels of signifIcance when compar q the ratin g s of the reference cycles with the rating of the treatment cycles with each treatment group, see Results.
Spouse's Rating
"pendent rating of the irritability and depressed
EXlOd displayed by the patient in the premenstrual phise was undertaken in at least one of the pretreat11m! reference cycles and in at least one of the treat11m! cycles by the spouses of 17 of the patients (11 in it clomipramine group, six in the placebo group). Whereas spouse's rating did not differ signifIcantly between groups during the two pretreatment reference cycles, the rating of irritability and depressed mood dur ing the treatment cycles was signifIcantly lower in the clomipramine treated group (see Fig. 8 ).
Global Assessment
As shown in Figure 9 , self-rated global improvement during treatment was signifIcantly more favorable . Global improvement during treatment as assessed shortly after the last treatment cycle by the subjects complet ing the trial . Bars represent number of subjects. No par ticipants reported a deterioration of premenstrual complaints during medication. EI = enormously improved, MI = much improved, SI = somewhat improved, NC = no change. The difference between the two groups was statistically signiftcant
in the clomipramine group than in the group given placebo.
Tolerability Data
All symptoms reported as possible side effects of the treatment by the patients completing the trial are shown in Table 1 . In addition, six subjects in the clomipramine group withdrew from treatment due to one or several unwanted effects. Five of these reported increased fa tigue, four reported dry mouth, one reported increased anxiety and suicidal thoughts, one reported sweating, and one reported vertigo. 
DISCUSSION
The present trial confIrms our previous observation (Eriksson et al. 1990; Sundblad et al. 1992 ) that low doses of the tricyclic antidepressant clomipramine � more effective than placebo in reducing premenstrual irritability and depressed mood. Thus, both with re spect to the daily rating of these symptoms and with respect to the global assessment of treatment, the women in the clomipramine group reported signifIcantly greater improvement than did patients treated with placebo.
The superiority of clomipramine to placebo also lends support from the symptom rating performed bythepa· tients' spouses; however, due to a large number of miss ing data, the outcome of the spouses' rating shoul d be interpreted with some caution.
Clomipramine is a strong although nonselective serotonin reuptake inhibitor (Carlsson et al. 1969; Hyt· tel and Larsen 1985) . Given the postulated involvement of serotonin in the control of mood and irritability as well as in other symptoms that may be part of PMS, such as anxiety and increased carbohydrate crav ing (see Eriksson and Humble 1990) , it is tempting to suggest that the drug reduces premenstrual complaints by facilitating serotonergic neurotransmission. In support for this assumption, recent reports indicate that the selective serotonin reuptake inhibitor fluoxetine, ad· ministered continuously throughout the menstrualcy cle, may also be effective in the treatment of PMS (Rickels et al. 1990; Stone et al. 1991; Menkes et a1. 1992; Wood et al. 1992) . Moreover, the serotonin selectivere uptake inhibitor paroxetine appears superior to the noradrenaline selective reuptake inhibitor maprotiline in the treatment of severe premenstrual complaints (M.
Hedberg, C. Sundblad, B. Andersch, and E. Eriksson.
to be published). The apparent lack of effect of the sero tonin reuptake inhibitor fluvoxamine on premenstrua1 complaints in the study by Veeninga et al. (1990) may be due to shortcomings in the trial design; for exam ple, in this trial the diagnosis of premenstrual syndrome was not confIrmed by daily symptom ratings before the initiation of treatment.
Women with severe premenstrual irritability and/(I depression (and fulhlling the diagnostic criteria d LLPDD according to DSM-III-R) were included in the present study regardless of whether they displayed.
other premenstrual complaints or not. Consequently, the effect evaluation was focused on irritability and depressed mood (which we believe are the core sym!" toms of PMS). However, in addition, the occ urrellC! and severity of tension, increased appetite and/orcar· bohydrate craving, breast tenderness, and bloalill were also rated daily by the participants. Whereas ten sion was signifIcantly more reduced by clomipramine than by placebo, the effects of clomipramine on the so matic symptoms premenstrual breast tenderness and bloating were less impressive. The fInding that mental symptoms, such as irritability and depression, respond markedly to a treatment not affecting the somatic symp !Oms of PMS may lead to the questioning of whether Ihese two groups of symptoms are indeed parts of the mne syndrome; alternatively, they should be regarded .epiphenomena, both related to the cyclical variation ilovarial activity but unrelated to each other and oc currin g irr espectively of each other. Hence, assessment of the severity of PMS by calculating the sum of the rat ingscores of a series of somatic and mental symptoms may be inappropriate.
According to the assumed involvement of seroto nin in the regulation of food intake (Wurtman 1990) ,
I serotonin reuptake inhibitor should be expected to I!duce appetite and carbohydrate craving. However, weight gain rather than weight loss is a common side effect of clomipramine when used for, for example, depression. Because the effect of more selective sero n reuptake inhibitors is generally a decrease in weight (Wise 1992) , this effect of clomipramine is prob IIJIy not due to the effect of the drug on serotonin re iptake; according to one hypothesis, the paradoxical effect of clomipramine on weight is due to serotonin-2 mptor antagonism (Bernstein 1987) . In line with previ GUS st udies on premenstrual changes in food intake (Both-Ortman et al. 1988 ), many, but not all, of the par licipants in the present trial displayed increased appe Ielcarbohydrate craving premenstrually. Interestingly, cbnipramine, more effectively than placebo, reduced Iflissymptom; moreover, no patients reported weight pin as a side effect of active treatment.
When used for the treatment of depression, panic lIisorder and OeD, clomipramine, as well as other IOIIOa mine reuptake inhibitors, usually requires be tween 1 and 2 weeks of treatment before marked �dal effects are evident and often several months Wore a maxi mal therapeutic response is achieved (Katz 1111. 1990; Modigh et al. 1992) . For this reason, it has .. questioned whether the serotonin (and/or nor _aline) reuptake inhibiting effects, which occur lImly after drug intake, indeed constitute the primary axle of action of the drugs. The most important con cbion of the present study is that a marked benefIcial tied of clomipramine on depressed mood and irrita _in the premenstrual phase does not require con bous medication (Sundblad et al. 1992 ) but can be ldUeved by intermittent treatment starting at ovula Iiln and terminating a few days after the onset of the IellS trual bleeding. Hence, the time lag between start Ifllledi cation and clinical effect is considerably shorter when clomipramine is used for PMS than when the "'sis used for depression, panic disorder, or OeD.
Weed , only 7 days after treatment was initiated, and lIIy 4days after the maximal dose of 50 to 75 mg had len reached, a marked symptom reduction was obClomipramine in the Premenstrual Syndrome 143 served in patients receiving active treatment (see Fig.  5 ). Whether the effect lag when using clomipramine for PMS is even shorter than four to seven days is diffIcult to decide from the present data. Notably, many PMS patients that we have treated with clomipramine in the premenstrual phase claim that a benefIcial effect may be experienced within less than 24 hours from drug in take provided that a dose of at least 25 mg is taken as starting dose; however, to exclude the placebo factor this impression has to be confrrmed in a placebo-con trolled trial. Interestingly, according to a previous re port by Brezinski and coworkers (1990) , the serotonin releasing agent fenfluramine also reduces premenstrual depression and carbohydrate craving when admini stered intermittently during luteal phases only. Also, a recent case report supports that fluoxetine has a very short onset of action when used for the treatment of premenstrual complaints (Daamen and Brown 1992) .
The difference in time lag when using clomipramine for PMS on the one hand, and for depression, panic disorder, and OeD on the other, may lead to the sug gestion that different modes of actions are involved when using the drug for the different conditions. Al ternatively, and perhaps more likely, the serotonin re uptake inhibition may always be the primary mode of action for clomipramine; however, some conditions may require a longer period of increased serotonergic activity before symptoms are remitted than others. The possibility that certain symptoms are likely to respond more quickly to antidepressants than others, regard less of the underlying condition, should also be con sidered. Irritability is one of the symptoms of PMS that responds quickly and dramatically to treatment with clomipramine; in depressed patients, hostility has re cently been shown to respond more rapidly to anti depressants than do other features of the depressive syndrome (Katz et al. 1991) .
The dosage required when using clomipramine (and probably also other serotonin reuptake inhibitors) also differs markedly depending on the condition that is to be treated. Thus, whereas 150 mg is usually recom mended as a daily dosage for the treatment of depres sion, even higher doses are often required for the treat ment of OeD. In contrast, both panic disorder (Gloger et al. 1981; Modigh et al. 1989 ) and PMS (Eriksson et al. 1990; Sundblad et al. 1992 ; present trial) usually re spond to considerably lower doses (i.e., 25 to 75 mg per day). As would be expected from the drug regimen applied, plasma concentrations of clomipramine and its metabolite desmethylclomipramine were low as com pared to the concentrations normally recommended for the treatment of depression.
Because no group given continuous medication with clomipramine was included in the present trial, it is not possible to conclude whether clomipramine given intermittently in the luteal phase only is as effec-tive as clomipramine given every day of the cycle . A comparison of the outcome of this trial and that of our earlier study on clomipramine given throughout the cy cle (Sundblad et al. 1992) indicates that continuous medication is in fact somewhat more effective than is intermittent treatment. Thus, the symptom reduction in percent of the ratings during the reference cycles was slightly higher in the trial using continuous medication (80% versus 70%). When comparing the two different trials, however, it should be noted that the patients reached somewhat higher mean doses of clomipramine in the trial using continuous medication.
In our experience, women with PMS, like patients with panic disorder , are more sen sitive to the side effects of clomipramine, such as sweat ing, dry mouth, and sexual impairment, than are de pressed patients. For this reason, the possibility that drug treatment can be restricted to the luteal phase and still be effective against PMS is of obvious practical im portance, especially for women with premenstrual com plaints lasting for less than 1 week before the menstru ation. On the other hand, for patients with symptoms of PMS starting around ovulation and terminating a few days after the menstrual bleeding has started, the symptom-free interval may be so short that a tapering of the medication is not meaningful . Also, it should be pointed out that for some patients, continuous adminis tration of clomipramine over the entire menstrual cy cle may be associated with milder side effects than in termittent administration. Thus, sometimes the most cumbersome unwanted effects of clomipramine are those appearing during the frrst days of treatment only to fade and vanish after a few days or weeks of drug administration. When using intermittent administra tion of clomipramine, in some patients this syndrome may reappear every time the patient starts the medica tion, that is, once every menstrual cycle; in contrast, when clomipramine treatment is chronic these symp toms are usually a problem only during the ftrst treat ment cycle. Notably, the number of drop outs due to side effects was larger in the present trial than in our previous study of clomipramine in PMS (Sundblad et al. 1992) , probably due to the fact that the escalation of dose was faster and that initial side effects in some patients reappeared for every new treatment period.
Needless to say, like in most drug trials using tricyclic antidepressant drugs, it cannot be excluded that the oc currence of side effects to some extent may have re duced the blindness on the part of the participants.
A third treatment strategy that we have success fully applied openly in a large number of PMS patients is the following. A very low dose of clomipramine (5 to 10 mg) is taken daily throughout the menstrual cy cle; in the beginning of the luteal phase, the patient in creases the dosage to a maximal dose of 25 to 75 mg, and when the menstrual bleeding starts the medication NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO. 2 is again tapered to the low maintenance dose. With this regimen, the reappearance of initial side effects � avoided, other side effects are minimized (especiall y during the follicular phase), and an impressive efficacy is achieved (c. Sundblad and E. Eriksson, unpublished observation) . Also, the possibility that an intermittent administration is rendered more effective if preceded by a few cycles of continuous medication should be taken into consideration (c. Sundblad and E. Eriksson, unpublished observation) .
In conclusion, the present trial demonstrates a short onset of action when using clomipramine for the treat· ment of PMS. We suggest that when clomipramine � used for this indication, the drug regimen should be individualized; thus, for some subjects continuous medication is preferable, whereas for others intermit tent treatment appears much more acceptable .
